Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Fuso Pharmaceutical Industries's EV-to-FCF or its related term are showing as below:
TSE:4538'
s EV-to-FCF Range Over the Past 10 Years
Min: -128.61 Med: -5.47 Max: 19.55
Current: -5.33
During the past 13 years, the highest EV-to-FCF of Fuso Pharmaceutical Industries was 19.55. The lowest was -128.61. And the median was -5.47.
TSE:4538's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs TSE:4538: -5.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fuso Pharmaceutical Industries's PE Ratio (TTM) for today is calculated as:
Fuso Pharmaceutical Industries's share price for today is 円2140.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fuso Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円235.621.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fuso Pharmaceutical Industries EV-to-FCF Related Terms
Fuso Pharmaceutical Industries EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fuso Pharmaceutical Industries's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fuso Pharmaceutical Industries EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fuso Pharmaceutical Industries's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fuso Pharmaceutical Industries's EV-to-FCF falls into.
Fuso Pharmaceutical Industries's current Enterprise Value is 円41,885 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fuso Pharmaceutical Industries's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-7,883 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuso Pharmaceutical Industries (TSE:4538) has a EV-to-FCF of -5.31 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fuso Pharmaceutical Industries and its competitors. According to the industry distribution chart, Fuso Pharmaceutical Industries ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Fuso Pharmaceutical Industries' EV-to-FCF too high?
Fuso Pharmaceutical Industries' current EV-to-FCF is -5.31. Based on the distribution chart, Fuso Pharmaceutical Industries ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Fuso Pharmaceutical Industries has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fuso Pharmaceutical Industries' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fuso Pharmaceutical Industries ranks #999999 out of 562 companies for EV-to-FCF. This places Fuso Pharmaceutical Industries in the lower half of its industry. The industry median EV-to-FCF is 21.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fuso Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuso Pharmaceutical Industries's current EV-to-FCF is -5.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuso Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries (TSE:4538) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,554.44, compared to a current price of 円2,140.00 — trading 16.2% below its estimated fair value. The current EV-to-FCF is -5.31. Fuso Pharmaceutical Industries' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fuso Pharmaceutical Industries (TSE:4538), the current EV-to-FCF is -5.31 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fuso Pharmaceutical Industries (TSE:4538) Overvalued in 2026?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries stock appears to be undervalued.
The current stock price of 円2,140.00 is trading 16.2% below its estimated GF Value™ of 円2,554.44.
GuruFocus considers Fuso Pharmaceutical Industries to be Modestly Undervalued.
Key valuation signals for TSE:4538:
EV-to-FCF: -5.31
GF Value™: 円2,554.44 vs. price of 円2,140.00 (16.2% below fair value)
No single metric tells the full story. See the TSE:4538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fuso Pharmaceutical Industries Business Description
Fuso Pharmaceutical Industries Ltd. is engaged in the manufacture and sale of pharmaceuticals and medical equipment. The company's main products are transfusion fluid and artificial kidney dialysis fluid. Company also includes real estate segment.
51GF Score
Get the complete analysis for TSE:4538
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4538 has been successfully added to your 
